Scale -


  • PBT is 16.31 Rs Cr; Continuous Growth over 3 years; Annual Decline is -1472 %
  • Quarterly Ebitda is 61.97 Rs Cr; Continuous Growth over 3 Quarters
  • Quarterly Profit is 16.31 Rs Cr; Continuous Growth over 3 Quarters
  • Ebitda is 193 Rs Cr; 5 Year CAGR is 18 %
  • PAT is -7.41 Rs Cr; Annual Decline is -1472 %; in Bottom Quartile

Profitability -


  • Quarterly Ebitda Margin is 16 %; Continuous Growth over 3 Quarters
  • Quarterly Profit margin is 4 %; Continuous Growth over 3 Quarters
  • PBDIT Margin is 14.09 %; 5 Year CAGR is 16 %; Annual Decline is -16 %
  • PAT Margin is -0.54 %; Annual Decline is -1450 %; in Bottom Quartile

Return -


  • Asset Turnover is 60 %; Continuous Growth over 3 years
  • ROCE is 6.48 %; Annual Decline is -28 %
  • ROA is -0.31 %; Annual Decline is -1650 %; in Bottom Quartile
  • ROE is -0.59 %; Annual Decline is -1575 %; in Bottom Quartile

Efficiency -


  • Quick Ratio is 0.6; Annual Growth is 36 %; Continuous Growth over 3 years; in Bottom Quartile
  • Current Ratio is 0.96; Continuous Growth over 3 years; in Bottom Quartile
  • Inventory Turnover Ratio is 4.31; Continuous Growth over 3 years; 5 Year CAGR is 22 %

Solvancy -


  • Debt/Equity is 0.53; Continuous Decline over 3 years; in Top Quartile
  • Total Debt is 665 Rs Cr; Continuous Decline over 3 years; in Top Quartile
  • Long term Debt is 110 Rs Cr; 5 Year CAGR is -21 %
  • Contingent Liabilities is 212 Rs Cr; Annual Growth is 267 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 33 %

Quality -


  • Change in Inventories/Total Expenses is 1 %; Annual Decline is -80 %
  • Operating cashflow/ebitda is 79 %; in Top Quartile; Annual Decline is -20 %
  • Current Tax/PAT is 0 %; in Bottom Quartile
  • Operating cashflow/PAT is -20.64 %; Annual Decline is -105 %; in Bottom Quartile
  • Exceptional Items/PBT is 79 %; in Top Quartile; 5 Year CAGR is 113 %

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Solara Active Pharma Sciences Ltd. Estimates – NSE:SOLARA
With EPS Growth And More, Solara Active Pharma Sciences (NSE:SOLARA) Makes An Interesting Case
Solara Active Pharma NSE:SOLARA Q2 FY27 Earnings Call Key Highlights
Solara Active Pharma Sciences: The Core Business Recovers, but Vizag Still Weighs
Solara Active Pharma Sciences Limited (SOLARA.NS) stock price, news, quote and history
Solara Active Pharma (NSE:SOLARA) Final Forfeiture Notice Oct 2026
Earnings Central: Solara’s best quarter in 5 years, LTM’s AI gains and Federal Bank’s solid Q2
Solara Active Pharma ?? ??????? ?????: Q2 ???? ???? **?28 ????** ?? ??????, ??????? **33%** ????
Solara Active Pharma Q2FY27 Results: EBITDA doubles 118% YoY to ?76.9 crore
Solara Active Pharma Sciences (NSE:SOLARA): What Do Q2 FY27 Results Reveal?
Solara Active Pharma share price zooms 16% on Q2 turnaround; H1 net up 103x
Solara Active Pharma shares jump nearly 18% from day’s low after Q2 turnaround
Solara Active Pharma shares rally 16% after posting net profit of ?28 crore in Q2 FY27; check all numbers
Solara Active Pharma to host analyst call on Oct 16 for Q2FY27 results
Solara Active Pharma Sciences (SOLARA.NS) Eases 0.90% to ?649.0, Holds Above ?616.55 Support Zone
Solara Active Pharma Sciences ESG Rating Upgrade FY26
Solara Active Pharma (NSE:SOLARA) Q2 FY27 Depository Certificate Filed
Solara Pharma approves forfeiture notice for unpaid rights shares